Genentech Halts Avastin Trial Enrollment Due To GI Perforations
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II study of bevacizumab in platinum-refractory ovarian cancer patients demonstrated a higher rate of GI perforations than previously seen in studies of the oncologic.
You may also be interested in...
Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy
NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.
Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy
NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.
Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says
The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.